drugset / Trial / NCT01993017

Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes

NCT01993017 ↗

RandomizedParallel-groupSingle-blindScreening

Summary

The purpose of this study is to examine, in a randomized controlled trial, the benefits and costs of the American Heart Association's (AHA) advisory for depression screen and treatment of post-acute coronary syndrome patients.

Timeline

Start
2013-11
Primary completion
2018-07-31
Completion
2019-07-31

Outcome

Missed primary endpoint

registry analysis (superiority test); AHA Depression Screen, Notify & Treat vs Depression Screen & Notify vs No Depression Screen; p = 0.98; ANOVA NCT01993017 ↗

paper There were no differences in mean (SD) change in quality-adjusted life-years (screen, notify and treat, -0.06 [0.20]; screen and notify, -0.06 [0.20]; no screen, -0.06 [0.18]; P = .98) PMID 31633746 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule — —
Subject Sertraline Small molecule — —